Evidence map›Paper›PMID 18081926›Full record

ArticleRetrovirology2007

Role of the long cytoplasmic domain of the SIV Env glycoprotein in early and late stages of infection.

Andrei N Vzorov, Armin Weidmann, Natalia L Kozyr, Vladimir Khaoustov, Boris Yoffe, Richard W Compans

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The cytoplasmic tail of retroviral envelope glycoproteins.Progress in molecular biology and translational science · 2015
    Review
  5. Article
  6. Article
  7. Palmitoylation of virus proteins.Biology of the cell · 2012
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Andrei N VzorovDept. of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, GA, USA. avzorov@emory.edu
Armin Weidmann
Natalia L Kozyr
Vladimir Khaoustov
Boris Yoffe
Richard W Compans
Atlanta VA Medical Center · USBaylor College of Medicine · USEmory University · USMorphoSys (Germany) · DE

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Novel VLP-Based Mucosal and Sytemic HIV VaccinesU19AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 2003 to 2009
$15.8M
POLIOVIRUS REPLICONS FOR HIV/SIV VACCINESP01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 1998 to 2002
$5.1M
VIRUCIDAL AND BACTERICIDAL PORPHYRINS--SYNTHETIC, MOLECULAR, ANALYTICAL STUDIESP01AI045883 · NIAID · EMORY UNIVERSITY · PI COMPANS, RICHARD W · 1999 to 2003
$3.6M
RECOMBINANT VACCINES DERIVED FROM POLIOVIRUSU01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 1989 to 1997
–
NIAID NIH HHS AI028147NIAID NIH HHS AI45883NIAID NIH HHS P01 AI028147NIAID NIH HHS P01 AI045883NIAID NIH HHS P30 AI050409NIAID NIH HHS U01 AI028147NIAID NIH HHS U19 AI028147
6 · The paper itself

Abstract

backgroundThe Env glycoproteins of retroviruses play an important role in the initial steps of infection involving the binding to cell surface receptors and entry by membrane fusion. The Env glycoprotein also plays an important role in viral assembly at a late step of infection. Although the Env glycoprotein interacts with viral matrix proteins and cellular proteins associated with lipid rafts, its possible role during the early replication events remains unclear. Truncation of the cytoplasmic tail (CT) of the Env glycoprotein is acquired by SIV in the course of adaptation to human cells, and is known to be a determinant of SIV pathogenicity.

resultsWe compared SIV viruses with full length or truncated (T) Env glycoproteins to analyze possible differences in entry and post-entry events, and assembly of virions. We observed that early steps in replication of SIV with full length or T Env were similar in dividing and non-dividing cells. However, the proviral DNA of the pathogenic virus clone SIVmac239 with full length Env was imported to the nucleus about 20-fold more efficiently than proviral DNA of SIVmac239T with T Env, and 100-fold more efficiently than an SIVmac18T variant with a single mutation A239T in the SU subunit and with a truncated cytoplasmic tail (CT). In contrast, proviral DNA of SIVmac18 with a full length CT and with a single mutation A239T in the SU subunit was imported to the nucleus about 50-fold more efficiently than SIVmac18T. SIV particles with full length Env were released from rhesus monkey PBMC, whereas a restriction of release of virus particles was observed from human 293T, CEMx174, HUT78 or macrophages. In contrast, SIV with T Envs were able to overcome the inhibition of release in human HUT78, CEMx174, 293T or growth-arrested CEMx174 cells and macrophages resulting in production of infectious particles. We found that the long CT of the Env glycoprotein was required for association of Env with lipid rafts. An Env mutant C787S which eliminated palmitoylation did not abolish Env incorporation into lipid rafts, but prevented virus assembly.

conclusionThe results indicate that the long cytoplasmic tail of the SIV Env glycoprotein may govern post-entry replication events and plays a role in the assembly process.

Indexed as

Adaptation, PhysiologicalAnimalsCell LineCytoplasmGene Products, envHumansProtein Structure, TertiarySimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVirus AttachmentVirus ReplicationGene Products, env

Identifiers

PMID18081926
PMCPMC2242802
OpenAlexW2148463680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.